News

Levetiracetam found superior to carbamazepine and valproate sodium in reducing Rolandic discharges on EEG of children with Rolandic epilepsy.

When providers fail to recognize and combat stigma in their ranks, undiagnosed persons with HIV may go unidentified and fail to get quality care and treatment.

A new review of literature about 2 anti-VEGF therapies for diabetic macular edema suggest the drugs hold promise, but not without some caveats.

Cannabidiol (Epidiolex), the first FDA-approved plant-derived cannabinoid medicine in the United States, is now available by prescription for patients with seizures associated with Lennox-Gastaut syndrome or Dravet syndrome.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.

The FDA has approved sufentanil sublingual tablet (Dsuvia) as a pain management therapy.

Aquestive Therapeutics’ clobazam (SYMPAZAN) oral film has been approved by the US Food and Drug administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years or older.

CMS said it responded to complaints about its 2019 Medicare Physician Fee Schedule (PFS)—which it finalized today—and will not collapse 5 billing codes down to 2, which had drawn an outcry from some medical associations that their care for complex patients would be shortchanged.

The use of marijuana for patients with multiple sclerosis can have a limited effect on symptoms such as spasticity, pain, and bladder dysfunction.

In absence of head-to-head trials between 2nd and 3rd generation antiepileptic drugs, a meta-analysis was used to identify suitable agents for monotherapy.

Recent clinical assessment of gastroesophageal reflux disease has linked it to an inflammatory response triggered by cytokines.

There are 3 FDA-approved medications available to treat opioid use disorder, and different treatment approaches that can aid patients on the road to recovery.

The chip was developed using cells from patients with and without ALS.

How the therapy is proving capable of giving patients the opportunity to slow down disease progression, while potentially increasing the health outcomes of patients and saving money.

Robert Chen, MD, and Hodgkin’s lymphoma patient, Jeremy Hernandez, speak on the challenges of receiving and treating a rare cancer diagnosis in young adults.

The FDA has approved Sandoz’s biosimilar, Hyrimoz (adalimumab-adaz), for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis in patients aged 4 years and older, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

Who is the best candidate for invasive treatment in the GERD population?

Martha L. Twaddle, MD, reviews new updates in the 4th edition of National Clinical Guidelines for Palliative Care.

A total of 85% of study participants achieved virologic suppression (viral load

Added stigma further burdens the treatment of patients with opioid use disorder, but the medical community can do something about it.

The FDA has approved Johnson & Johnson’s canagliflozin (INVOKANA) for patients with type 2 diabetes who have established cardiovascular disease in order to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, or death.

Other risk factors included the age of conception, with women younger than 18 or older than 37 being at greatest risk.

The brain’s lymphatic vessels may offer a new way to treat multiple sclerosis.

The US Food and Drug Administration has approved TherapeuticsMD's TX-001HR (BIJUVA) for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.

Sodium oxybate (Xyrem) has been approved by the FDA for the treatment of cataplexy and excessive daytime sleepiness in pediatric patients aged 7 to 17 years old with narcolepsy.

How increasing obesity rates have affected the prevalence of GERD and re-prioritized first-line care.

Lindsey Jennings, MD, MPH, and Carolyn Bogdon, MSN, FNP-BC, of Medical University of South Carolina discuss the challenges facing health care providers who are on the front line of battling the opioid epidemic.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.